Thursday, 25 May 2017

Design of Experiments (DoE) for Process Development and Validation

Design of Experiments (DoE) is a very important process development and validation component in several kinds of industries. DoE for process development and validation involves carrying out a number of tests recurrently and steadily over a period of time. Its responses are then observed.
DoE is important for process development and validation as it offers an understanding of the predictability and reproducibility of an experiment. Fundamentally, Design of Experiments for process development and validation seeks to rule out fluke or chance in the methods needed for bringing about control for a product.
DoE in medical devices
In the area of medical devices, guidelines for Design of Experiments for process development and validation are set out in the Global Harmonization Task Force (GHTF) Process Validation Guidance for Medical Device Manufacturers. This document offers guidance in the area of Design of Experiments for process development and validation by suggesting the exact areas in which design of experiments should be applied during Process Validation.
The GHTF guidance also suggests the use of both screening and response surface designs during Operational Qualification. It further requires Design of Experiments for process development and validation to be used during various phases of design controls. These include:
o  Design verification
o  Design validation
o  Design transfer
o  Design changes.
Get a full understanding of Design of Experiments for process development and validation
The ways of approaching Design of Experiments for process development and validation will be topic of a two-day seminar that is being organized by GlobalCompliancePanel, a highly respected provider of professional trainings for the areas of regulatory compliance.
Jim Wisnowski, who is the cofounder of Adsurgo LLC and co-author of the book Design and Analysis of Experiments by Douglas Montgomery: A Supplement for using JMP, will be the Director at this seminar. In order to gain a full understanding of the principles and application of Design of Experiments for process development and validation; please register for this seminar by visiting Design of Experiments (DoE) for Process Development and Validation
This seminar has been pre-approved by RAPS as eligible for up to 12 credits towards a participant's RAC recertification upon full completion.
All about Design of Experiments for process development and validation
This seminar will offer total and all-round understanding of all the aspects of Design of Experiments for process development and validation.
Process development studies need to be completed before a process control plan is developed as part of an overall risk management strategy. These process development studies help gain knowledge and understanding about the impact of variation in process parameters on the variation in the product quality characteristics of the product.
An explanation of the methods used
The methodology of Design of Experiments for process development and validation offers a means for identifying process parameters, which impact product quality (critical process parameters) and determine the functional relationship that links the process parameters to those critical quality attributes.
Design of Experiments for process development and validation uses screening designs such as 2k factorial and D-optimal designs to determine critical process parameters. Design of Experiments for process development and validation use response surface designs, such as Central Composite Designs (CCDs) and I-optimal designs for fashioning the functional relationship between those critical process parameters and the critical quality attributes.
A primer on statistical analysis
This seminar on Design of Experiments for process development and validation will present a primer on statistical analysis, during which it will focus on the methods required for analysis of designed experiments. Jim will then move on to the steps to a proper DoE, during the process of which he will demonstrate the nature and uses of important risk management tools such as Ishikawa and FMEA, which can be used pre and post DOE studies.
The Director will also teach how to generate and analyze multiple screening and response surface designs, and why and how each are used. After teaching participants how to present the results, Jim will explain how to update the risk management tools using the results of the studies.
This session on Design of Experiments for process development and validation will cover the following areas:
o  Identify critical quality attributes (CQAs) that will be used as responses in your designs
o  Utilize risk management tools to identify and prioritize potential critical process parameters
o  Identify critical process parameters and develop a functional relationship between those process parameters and your critical-to-quality attributes (CQAs) using both screening and response surface designs
o  Be able to design and analyze screening designs including a factorial, fractional factorial, and D-optimal design
o  Understand the need for adding center points to a design
o  Be able to design and analyze response surface designs including central composite designs (CCDs), Box-Behnken designs, and I-optimal designs
o  Use systematic understanding from DOE studies to update the control plan that is part of the overall risk management plan.

Labels: , , , , , ,

Wednesday, 16 November 2016

An understanding of HIPAA upcoming changes for 2016

Professionals at various levels of the healthcare industry need to have a grasp of the HIPAA Security/Privacy Rule and the way it relates to their practice or business. A two-day, in person, live seminar being organized by GlobalCompliancePanel, a leading provider of professional trainings for the regulatory compliance areas, will offer this very important understanding.

Brian Tuttle, a Certified Professional in Health IT (CPHIT), Certified HIPAA Professional (CHP), and Certified Business Resilience Auditor (CBRA) , who brings over 15 years’ experience in Health IT and Compliance Consulting, will be the speaker at this seminar. Please log on to http://www.globalcompliancepanel.com/control/globalseminars/~product_id=900727SEMINAR to enroll for this highly educative session.

A host of areas relating to HIPAA and changes for 2016

Among the areas that Brian will take up are the changes under the Omnibus Rule and any other applicable updates for HIPAA for 2016. There are an enormous amount of issues and risks that Covered Entities and Business Associates these days. He will also dwell upon other aspects of HIPAA, such as:
o   The history of HIPAA
o   Privacy vs. security,
o   Business Associates,
o   Changes for 2016
o   Audit process
o   Paper-based PHI
o   HIPAA and suing
o   Texting
o   Email
o   Encryption
o   Medical messaging
o   Voice data, and lots more.
Myths vs. realities of HIPAA

Essentially, Brian will explain myths versus reality as it relates to this very enigmatic law, and this clarification will be based on over 1000 risk assessments he has performed during the many years of experience he gained in dealing directly with the Office of Civil Rights HIPAA auditors during his career.

Understanding the risk factors for being sued for wrongful disclosures

He will also speak of real life audits conducted by the Federal government and help participants understand what their highest risks are for being fined. He will discuss the highest risk factors for being sued for wrongful disclosures of PHI and the manner in which patients are now using State laws to sue for wrongful disclosures.

He will offer an explanation of the multiple litigated cases that he has been a part of involving HIPAA situations. He will also thoroughly explain how patients are now able to get cash remedies for wrongful disclosures of private health information and demonstrate how to limit those risks by simply taking proactive steps and utilizing best practices.

Brian will cover the following areas at this seminar:

o   History of HIPAA
o   HITECH
o   HIPAA Omnibus Rule
o   How to perform a HIPAA Security Risk Assessment
o   What is involved in a Federal audit and how is it conducted
o   Risk factors for a federal audit
o   EHR and HIPAA
o   Business Continuity/Disaster Recovery Planning
o   Business Associates and HIPAA
o   In depth discussions on IT down to the nuts and bolts
o   BYOD
o   Risk factors that can cause an audit (low hanging fruit)
o   New rules which grant states ability to sue citing HIPAA on behalf of a patient
o   New funding measures.




Labels: , , , , , , ,